Skip to content
Global markets · Independent coverage Follow a hub and receive new coverage by email.
Artificial IntelligenceNASDAQ:AEHRStock Market

Aehr Stock Rebounds 13%. The Revenue Guide Still Has to Earn a $2.81 Billion Valuation

4 min read
Roman PerkowskiRoman Perkowski

FREMONT, California, Sept. 4, 2026, 11:47 p.m. EDT — Aehr Test Systems NASDAQ:AEHR jumped 13.1% on Friday, closing at $86.26 on heavy volume. There was no new order or earnings release to explain the move.

The rebound puts the valuation back under a bright light. At Friday’s close, Aehr’s 32.62 million shares were worth about $2.81 billion. That is 18.8 to 21.6 times management’s entire fiscal 2027 revenue forecast.

Growth could be exceptional. The price already asks for it.

A 13% Friday jump did not erase the August break

Daily closes, U.S. dollars, Aug. 3 through Sept. 4

Friday close $86.26Friday +13.1%From Aug. 17 close −40.8%Volume 4.50m
Aehr shares rose from 91 dollars and 71 cents on August 3 to a closing peak of 145 dollars and 61 cents on August 17, then fell to 86 dollars and 26 cents by September 4. $150$125$100$75 $145.61 peak$86.26 Aug. 3Aug. 17Sept. 4 Mobile chart of Aehr daily closes from August 3 through September 4. 15012510075 145.6186.26Aug. 3Aug. 17Sept. 4

Close as of . Source: Yahoo Finance historical market data. Percentage comparisons use unadjusted closes; volume is reported exchange volume.

Friday’s 4.50 million shares were roughly 1.8 times the recent average reported by Fox Business. Yet the stock remains 40.8% below its Aug. 17 closing peak of $145.61.

The company’s only fresh release, dated Thursday, announced investor meetings at a Sept. 10 Lake Street conference. It contained no new financial target. The rally therefore looks like a repricing of known facts, not a response to a disclosed contract.

Those known facts are powerful. Aehr forecast fiscal 2027 revenue of $130 million to $150 million, up 160% to 200% from last year’s $50.0 million. It also projected non-GAAP net income equal to 18% to 22% of revenue.

The guide leaves little room for a multiple reset

Friday valuation against company guidance; TS2 calculations

CLOSE-BASED EQUITY VALUE$2.81bn$86.26 × 32.62m shares
FY2027 REVENUE GUIDE$130m–$150m160%–200% projected growth
EQUITY VALUE / SALES21.6×–18.8×low to high revenue case
NON-GAAP INCOME GUIDE$23.4m–$33.0mrevenue × guided margin
Last reported $100.6m effective backlog as a share of guidance
$130m revenue case77.4%
$150m revenue case67.1%
Read this carefully: backlog is not guaranteed revenue. The $100.6 million figure was reported July 14. Aehr’s later $22 million order is real, but shipments and other bookings changed after that date, so it cannot simply be added to produce a current backlog balance.

Sources: Aehr’s fiscal 2026 results and guidance and its Form 10-K. Equity value uses the July 20 share count and Friday close.

The $100.6 million effective backlog reported on July 14 covered 67% to 77% of the revenue guide. Then came a $22 million follow-on order on Aug. 12 from Aehr’s lead AI-processor customer.

Aehr expects to ship those FOX-XP systems and wafer contactors over six months. The order alone equals 14.7% to 16.9% of the annual revenue forecast. That is meaningful, though not the same as booked profit.

Chief Executive Gayn Erickson said this week that Aehr was seeing “strong traction with AI processors” in both wafer-level and package-level formats. Investors will hear the pitch again in New York on Thursday.

Analysts still point higher — from a small sample

Published 12-month targets tracked through Aug. 14 versus Friday’s close

Current
$86.26
Low
$110
Average
$130
High
$175
ANALYST COUNT5small-cap coverage remains thin
CONSENSUSStrong BuyS&P Global poll
AVERAGE UPSIDE50.7%from Friday’s close
TARGET SPREAD$65wide range signals uncertainty
The catch: these targets predate the latest selloff and rebound. A five-analyst consensus is context, not proof that the market has mispriced the stock.

Source: S&P Global analyst data compiled by StockAnalysis, last updated Aug. 14, 2026. Upside percentages are TS2 calculations using the Sept. 4 close.

The bull case is easy to state. AI chips are getting more costly, while advanced packages combine processors, high-bandwidth memory and other components. Catching a defective die before assembly can save a manufacturer far more than the test itself.

Aehr’s system tests nine 300-millimeter wafers at once. Its proprietary WaferPak contactors also create recurring demand as customers add capacity. The business can therefore scale faster than a simple machine count suggests.

But the concentration is sharp. Aehr’s five largest customers supplied 70% of fiscal 2026 revenue. Its top three contributed 26%, 14% and 11%, according to the 10-K.

One delayed production ramp can move a quarter. The $22 million order came from an unnamed lead customer, making the customer’s capacity plan unusually important to the annual forecast.

The balance sheet offers protection, with $116.5 million of cash and restricted cash at fiscal year-end. Much of the increase came from issuing stock. Aehr raised $97.4 million net through public offerings during fiscal 2026, including an April at-the-market program.

Risks: backlog can be delayed or cancelled, AI spending can shift between customers, and a 19-times-sales valuation can contract even if revenue grows. Non-GAAP margin excludes costs that still affect shareholders. Fresh equity issuance also showed that dilution is not theoretical.

The next useful number is not another conference appearance. It is revenue converted from backlog, followed by cash generated from that revenue. Friday’s rally bought investors a better mood. It did not lower the execution bar.

Sources

Roman Perkowski

About the author

Roman Perkowski

Roman Perkowski is a senior markets reporter at TechStock² covering company news, technology shares and economic developments across global equity markets. He graduated from the Cracow University of Economics and previously worked in investment research and corporate finance. Follow him on Google News.